This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Stearoyl-CoA Desaturase-1 Inhibitor
Valeant Pharmaceuticals International, Inc.
Drug Names(s): SCD1 Inhibitor
Description: Stearoyl-CoA Desaturase-1 (SCD1) Inhibitor is a proprietary compound that affects the SCD-1 enzyme, which is crucial to fatty acid metabolism.
Deal Structure: The Stearoyl-CoA Desaturase-1 (SCD1) Inhibitor was originally developed by Pfizer.
In July 2009, Graceway licensed the worldwide commercial rights for three investigational dermatological molecules, including the SCD1 inhibitor, from Pfizer.
In November 2011, Medicis announced that it was the successful bidder at a bankruptcy auction conducted by Graceway Pharmaceuticals for substantially all of the outstanding U.S. and Canadian pharmaceutical assets of Graceway. The transaction closed in December 2011.
Partners: Pfizer Inc.
Stearoyl-CoA Desaturase-1 Inhibitor News
Additional information available to subscribers only: